ArticleJournal of virology2026
Enhancing HIV-1-specific CAR-T cell functional activity by treatment with a novel cytokine-based scaffold with IL-15 superagonist and TGF-β-neutralizing activity.
Sara Lamcaj, Erin Cole, Christopher Hiner, Marta Santos Bravo, Jian Hua Zheng, Niraj Shrestha, Gregory Sowd, Ying Xiong, Zhongyu Zhu, Boro Dropulic and 2 more
Abstract read
In one paragraphArticle in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Sara LamcajDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.ORCID 0000-0001-8842-4518 Erin ColeDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Christopher HinerDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Marta Santos BravoDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Jian Hua ZhengDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Niraj ShresthaHCW Biologics Inc., Miramar, Florida, USA.
Gregory SowdCaring Cross, Gaithersburg, Maryland, USA.
Ying XiongCaring Cross, Gaithersburg, Maryland, USA.
Zhongyu ZhuCaring Cross, Gaithersburg, Maryland, USA.
Boro DropulicCaring Cross, Gaithersburg, Maryland, USA.
Hing C WongHCW Biologics Inc., Miramar, Florida, USA.
Harris GoldsteinDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.ORCID 0000-0003-0543-6025 Funding
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI Ulrich Steidl · 1985 to 2026
$111.2MPatient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Vinayaka R. Prasad · 2017 to 2026
$28.3MTraining in HIV/AIDS Pathogenesis; Basic and Translational ResearchT32AI007501 · NIAID · YESHIVA UNIVERSITY · PI PRASAD, VINAYAKA R. · 1995 to 2024
$6.6MAmplifying and Redirecting CMV-specific CD8 T cells to provide sustained control of HIV infectionR01AI172607 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI ALMO, STEVEN C., GOLDSTEIN, HARRIS · 2022 to 2025
$4.4MNovel Biologics Designed to Mobilize HIV-specific CTL for Sustained HIV RemissionR01AI145024 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI ALMO, STEVEN C., GOLDSTEIN, HARRIS · 2019 to 2023
$4.1MDeveloping and evaluating cell-specific lentivectors capable of selective in vivo generation of anti-HIV T cells to cure HIVR01AI174275 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI HARRIS GOLDSTEIN · 2024 to 2026
$2.2MNational Institute of Allergy and Infectious Diseases P30AI124414National Institute of Allergy and Infectious Diseases R01AI145024National Institute of Allergy and Infectious Diseases R01AI172607National Institute of Allergy and Infectious Diseases R01AI174275National Institute of Allergy and Infectious Diseases T32AI007501NCI NIH HHS P30 CA013330NIAID NIH HHS P30 AI124414NIAID NIH HHS R01 AI145024NIAID NIH HHS R01 AI172607NIAID NIH HHS R01 AI174275NIAID NIH HHS T32 AI007501
6 · The paper itselfAbstract
Chimeric antigen receptor T cell (CAR-T cell) therapy targeting and eliminating HIV-infected cells offers a promising approach to provide people living with HIV (PLWH) with a functional cure by preventing the recurrence of viremia caused by reactivation of latent HIV-1-infected cells. We previously described a bispecific CAR-T cell targeting two highly conserved gp120 epitopes (duoCAR-T cell) with potent anti-HIV-1 activity that is currently in clinical trials. However, elevated levels of transforming growth factor β (TGF-β) present in many PLWH may hinder the activity of both infused HIV-1-specific CAR-T cells, such as duoCAR-T cells and endogenous HIV-1-specific CD8
Indexed as
HIV-1HIV InfectionsInterleukin-15Receptors, Chimeric AntigenTransforming Growth Factor betaCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHIV Envelope Protein gp120Host-Directed TherapyHumansHIV Envelope Protein gp120IL15 protein, humanInterleukin-15Receptors, Chimeric AntigenTransforming Growth Factor betacapsidCAR-T cellsDuoCAR-T cellsgp120/gp41HIV-1HIV cure strategyIL-15immune modulationimmune suppressionimmunotherapyp24TGF-β
Identifiers
PMID42599109
PMCPMC13595942
What OpenQuestion holds
Textmetadata
Read underepoch 390